PANAJI: The USA-based Glenmark Generics Inc’s (GGI) focus on strategic planning and development has generated a robust pipeline in varying stages of maturity. The company, the North American division of Glenmark Generics Ltd has over 45 abbreviated new drug applications (ANDA’s) filed with the FDA pending approval.

In addition to its internal filings, Glenmark has engaged in external development partnerships to supplement and accelerate the growth of its existing pipeline.
Due to the strength and aptitude of its API team many of Glenmark’s generic products enjoy the added benefit of vertical integration. This provides Glenmark with a competitive edge in the industry, realization of better margins and organic symmetry. Striving to enhance its capabilities and differentiate itself from the competition, Glenmark is consistently building upon its portfolio and marketing an assortment of dosage form products from various therapeutic categories.
The company vice president (quality head) Mr Nitin Tiwari said: ‘’The Company is exploring its expertise into key arenas as hormones, and other niche segments. Glenmark looks to utilize routes of administration such as extended release tablets and capsules, semi-solid preparations, solutions and suspensions, injectables and other platform technology products. Strong operational capabilities mixed with the opportunities available from possible new mergers and acquisitions provide the ability to achieve the Company’s goals.’’
In a short span of five years, the Company saw growth in all areas and gained an impressive reputation in the industry as a driving force among its competition. GGI is currently authorized to distribute 49 products which generate a finished dosage marketing portfolio yielding over 175 sku’s (a mix of solid oral dosage and semi-solid preparations). GGI’s products have high market penetration rates and double digit share almost across the board.
Glenmark Generics Limited registered revenue of Rs 1,026 crore for the first year ended Mar 31, 2009 after the established of April 2008. Glenmark has built an impressive infrastructure and strengthened. Its integration across the pharmaceutical value chain through operations across its various manufacturing plants in 2003, he added.